Wednesday, June 19, 2024

Press Release from NCI: Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma

National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are subscribed to Press Releases from the National Cancer Institute. New press releases are listed below.

 

 

Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma
06/19/2024
More than half of clinical trial participants treated with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) had substantial tumor shrinkage. Of those, 38% had tumors that disappeared completely.
This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Bill Clinton Backing Biden Replacement???

Do you want to see who I believe will be the next president of the U.S.A? ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ...